Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.46 |
| ▸ | THRA | P10827 | 1/20 | 0.45 |
| ▸ | ACACB | O00763 | 1/20 | 0.45 |
| ▸ | NCF1 | P14598 | 2/20 | 0.44 |
| ▸ | EGFR | P00533 | 1/20 | 0.44 |
| ▸ | ILK | Q13418 | 1/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | RECQL | P46063 | 1/20 | 0.44 |
| ▸ | NQO1 | P15559 | 1/20 | 0.43 |
| ▸ | APP | P05067 | 10/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4061378 | 0.85 | NQO1 (0.57) | L3MBTL1THRAACACBNCF1KDM4E | |
| SCHEMBL20969950 | 0.85 | PRSS1 (0.41) | NQO1APP | |
| SCHEMBL9150174 | 0.83 | KDM4E (0.56) | L3MBTL1THRANCF1KDM4ERECQL | |
| SCHEMBL14653334 | 0.83 | KDM4E (0.50) | EGFRILKKDM4ERECQLAPP | |
| SCHEMBL163688 | 0.82 | LTA4H (0.52) | L3MBTL1ACACB | |
| SCHEMBL1007565 | 0.82 | LTA4H (0.53) | — | |
| SCHEMBL8218168 | 0.81 | NQO1 (0.67) | L3MBTL1THRANCF1KDM4ERECQL | |
| SCHEMBL163203 | 0.81 | NQO1 (0.67) | KDM4ENQO1 | |
| SCHEMBL1772406 | 0.81 | EGFR (0.45) | L3MBTL1NCF1EGFRILKKDM4E | |
| SCHEMBL25345889 | 0.81 | ALDH1A1 (0.57) | L3MBTL1THRAACACBNCF1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100324259-A1 | HYBRID BLOCK COPOLYMER MICELLES WITH MIXED STEREOCHEMISTRY FOR ENCAPSULATION OF HYDROPHOBIC AGENTS | INTEZYNE TECHNOLOGIES, INC. (US) | 2010-12-23 | — | — | US | disclosed |
| US-20100136063-A1 | Immunotherapy for Treatment of Amyloid-Related Disorders Using Encapsulated Beta-Amyloid Peptides | UNIVERSITY OF SOUTH FLORIDA (US) | 2010-06-03 | — | — | US | disclosed |
| US-7618944-B2 | Encapsulating in micelle which is a block copolymer containing hydrophilic and hydrophobic blocks | INTEZYNE TECHNOLOGIES, INC. (US) | 2009-11-17 | — | — | US | disclosed |
| US-7612153-B2 | conjugate polymer drugs; endcapped polyethers; nontoxic, biocompatible, non-immunogenic, soluble in water and other solvents | INTEZYNE TECHNOLOGIES, INC. (US) | 2009-11-03 | — | — | US | disclosed |
| US-20080274965-A1 | ENCAPSULATED AMYLOID-BETA PEPTIDES | INTEZYNE TECHNOLOGIES, INC. (US) | 2008-11-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100136063-A1 | Immunotherapy for Treatment of Amyloid-Related Disorders Using Encapsulated Beta-Amyloid Peptides | IAPP, APP, TTR | L3MBTL1 1018/4885THRA 3614/4885ACACB 1466/4885 |
| US-20080274965-A1 | ENCAPSULATED AMYLOID-BETA PEPTIDES | IAPP, APP, TTR | L3MBTL1 2428/4885THRA 3319/4885ACACB 2065/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.